NASDAQ: IOVAIovance Biotherapeutics Inc Stock
$3.63+0.19 (+5.52%)
Updated Mar 27, 2025
IOVA Price
$3.63
Fair Value Price
-$0.12
Market Cap
$1.19B
52 Week Low
$3.33
52 Week High
$14.77
P/E
-2.84x
P/B
1.68x
P/S
13.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$164.07M
Earnings
-$372.18M
Gross Margin
24.4%
Operating Margin
-228.56%
Profit Margin
-226.8%
Debt to Equity
0.28
Operating Cash Flow
-$353M
Beta
1.35
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IOVA Overview
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IOVA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IOVA
Ranked#122 of 477
Ranked#122 of 477
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.58 | A | |
| $8.46 | A | |
| $126.40 | A |
Be the first to know about important IOVA news, forecast changes, insider trades & much more!
IOVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IOVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IOVA ($3.63) is overvalued by 3,240.94% relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IOVA ($3.63) is not significantly undervalued (3,240.94%) relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IOVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IOVA due diligence checks available for Premium users.
Valuation
IOVA fair value
Fair Value of IOVA stock based on Discounted Cash Flow (DCF)
Price
$3.63
Fair Value
-$0.12
Undervalued by
3,240.94%
IOVA ($3.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IOVA ($3.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IOVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IOVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.84x
Industry
-123.64x
Market
31.08x
IOVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
4.52x
IOVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IOVA's financial health
Profit margin
Revenue
$73.7M
Net Income
-$78.6M
Profit Margin
-106.6%
IOVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IOVA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$910.4M
Liabilities
$200.0M
Debt to equity
0.28
IOVA's short-term assets ($457.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IOVA's short-term assets ($457.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IOVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IOVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$73.3M
Investing
$23.7M
Financing
$2.3M
IOVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IOVA vs Biotech Stocks
Iovance Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.